{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+Hydrochloride+%28DOX%29&page=22", "query": { "intervention": "Doxorubicin Hydrochloride (DOX)", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1374, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+Hydrochloride+%28DOX%29&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+Hydrochloride+%28DOX%29&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T01:13:33.477Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003207", "title": "Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "PSC 833", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "1998-03", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003207" }, { "nct_id": "NCT02293109", "title": "Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "carfilzomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mehrdad Abedi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 10, "start_date": "2015-12-17", "completion_date": "2018-01-11", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02293109" }, { "nct_id": "NCT00217425", "title": "Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2006-09-14", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 110, "location_summary": "Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217425" }, { "nct_id": "NCT00003540", "title": "Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "1998-06", "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003540" }, { "nct_id": "NCT00126191", "title": "Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Burkitt Lymphoma", "Non-Hodgkins Lymphoma", "Atypical Burkitt Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2005-07", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2013-05-23", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126191" }, { "nct_id": "NCT00116961", "title": "Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-02-07", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116961" }, { "nct_id": "NCT01098266", "title": "NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "NGR-hTNF plus Best Investigator's Choice (BIC)", "type": "DRUG" }, { "name": "Placebo plus Best Investigator's Choice (BIC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AGC Biologics S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2010-04-12", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 7, "location_summary": "Corona, California • Duarte, California • Tampa, Florida + 4 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098266" }, { "nct_id": "NCT02049905", "title": "Phase 3 Study to Treat Patients With Soft Tissue Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma" ], "interventions": [ { "name": "Aldoxorubicin", "type": "DRUG" }, { "name": "Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 433, "start_date": "2014-01", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049905" }, { "nct_id": "NCT00124956", "title": "Doxorubicin Pharmacokinetic (PK) Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 0, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-09-11", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124956" }, { "nct_id": "NCT00194753", "title": "Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasm" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2001-12", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2012-09-13", "last_synced_at": "2026-10-16T01:13:33.477Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00194753" } ] }